TrialPsychopharmacology2026

Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.

Lieuwe Appel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.